AFFYMETRIX (AFFX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX)

AFFX 14.01

0.0%

Apr 1 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Richard Haugland who wrote (805)	10/7/1998 4:32:00 PM
From: lnkennedy	Read Replies (1) of 1728

To J F et al: What's the advantage to AFFX with this deal? And does it give them more leverage over hyseq and incyte? BOULDER, Colo. -- Xenometrix Inc. (XENO) granted a non-exclusive license for its gene expression profiling technology to Affymetrix Inc. (AFFX). Financial terms weren't disclosed. In a press release Wednesday, Xenometrix said the license covers the collection of certain gene expression profiles using all methods, including high-density DNA arrays. Xenometrix is a biotechnology company with proprietary gene expression profiling technology. All replies welcome. good investing,lnk

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next